ING Group’s Bioverativ Inc. Common Stock BIVV Stock Holding History

ING Group’s Portfolio BIVV Stock Details BIVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-10,345	Closed	-$558K	–	875
2017 Q4	$558K	Sell	10,345 -5,135	-33%	-$281K	0.01%	476
2017 Q3	$883K	Buy	15,480 +9,615	+164%	+$563K	0.02%	342
2017 Q2	$353K	Buy	+5,865	New	+$334K	0.01%	637

Other funds holding BIVV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ACS

Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

ING Group's BIVV Position: Q1 2018 in Review

ING Group sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 10,345 shares — an estimated $558K sold.

ING Group first reported a position in BIVV in Q2 2017 and held it in 3 quarters. The position peaked at $883K in Q3 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

ING Group reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
ING Group sold 10,345 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $558K.
ING Group first reported a position in Bioverativ Inc. Common Stock in Q2 2017 and held it in 3 quarters.
ING Group's Bioverativ Inc. Common Stock position peaked at $883K in Q3 2017.
2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on ING Group's 13F filing for Q1 2018, filed 7 May 2018.